U.S. Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
81.52-1.25 (-1.51%)
At close: 5:35PM CEST
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Full screen
Previous Close82.77
Open82.75
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range81.28 - 83.30
52 Week Range66.72 - 92.97
Volume2,988,091
Avg. Volume2,460,430
Market Cap99.45B
Beta0.74
PE Ratio (TTM)11.28
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield3.30 (3.50%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacksyesterday

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

  • Reutersyesterday

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.

  • Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
    Zacksyesterday

    Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

    Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.